To access this material please log in or register

Register Authorize

Possibilities of administration of metoprolol succinate at cardiovascular diseases

Evdokimova A. G., Kovalenko E. V., Lozhkina M. V., Evdokimov V. V.

Keywords: treatment, metoprolol succinate, cardiovascular diseases

DOI: 10.18087/rhj.2012.5.1718

The review provides data concerning clinical efficiency of metoprolol succinate at treatment of AH, CHD, CHF. Sustained release dosage form of metoprolol succinate (Metozoc) provides convenient intake of the drug once a day, good tolerance, and very good treatment conformity.
  1. Арутюнов Г. П. Бета – блокаторы и сердечная недостаточность. Журнал Сердечная Недостаточность. 2002;3 (1):27–28.
  2. Рациональная фармакотерапия сердечно-сосудистых заболеваний: Рук. для практических врачей. Е. И. Чазов, Ю. Н. Беленков, Е. О. Борисова, Е. Е. Гогин и др.; Под общ. ред. Е. И. Чазова, Ю. Н. Беленкова. – М.: «Литтерра», 2005. – 972.
  3. Терещенко С. Н., Джаиани Н. А. Метопролол в терапии сердечно-сосудистых заболеваний. Справочник поликлинического врача. 2007;5 (3):16–19.
  4. Белоусов Ю. Б., Леонова М. В., Манешина О. А. и др. Метопролол сукцинат и тартрат: влияет ли соль на эффективность препарата? Фарматека. 2006;19 (134):14–19.
  5. Диагностика и лечение хронической сердечной недостаточности. В сб. «Национальные клинические рекомендации». – МЕДИ Экспо, 2010. – c.464–500.
  6. Чазова И. Е. β-Адреноблокаторы: место их применения при артериальной гипертонии в современных условиях. Системные гипертензии. 2010;2:4–7.
  7. Carruthers G, Shearer R, Taylor W, Moore M. A comparison of a controlled release (CR / ZOK) formulation of metoprolol, once daily, with conventional metoprolol tablets, twice daily, in mild to moderate hypertension. J Clin Pharmacol. 1990;30 (2 Suppl): S61–65.
  8. Sandberg A, Abrahamsson B, Regårdh CG et al. Pharmacokinetic and biopharmaceutic aspects of once daily treatment with metoprolol CR / ZOK: a review article. J Clin Pharmacol. 1990;30 (2 Suppl): S2–16.
  9. LuckerP, Moore G, Wiselgren I et al. Pharmacokinetic and pharmacodynamic comparison of metoprolol CR / ZOK once daily with conventional tablets once daily and in divided doses. J Clin Pharmacol 1990; 30 (Suppl.): S17–27.
  10. Warrington SJ, Barclay SP, John VA et al. Comparison of single-dose pharmacokinetic and pharmacodynamic properties of two metoprolol Oros systems with different initial zero-order release rates. Br J Clin Pharmacol. 1985;19 (Suppl 2):225S-230S.
  11. Диагностика и лечение артериальной гипертензии. В сб. «Национальные клинические рекомендации». – МЕДИ Экспо, 2010. – с. 5–34.
  12. Jäättelä A, Baandrup S, Houtzagers J, Westergren G. The efficacy of low dose metoprolol CR / ZOK in mild hypertension and in elderly patients with mild to moderate hypertension. J Clin Pharmacol. 1990;30 (2 Suppl): S66–71.
  13. Klein G, Berger J, Olsson G, Menzel T. A double-blind comparison of metoprolol CR / ZOK 50 mg and atenolol 50 mg once daily for uncomplicated hypertension. J Clin Pharmacol. 1990;30 (2 Suppl): S72–77.
  14. Omvik P, Leer J, Istad H, Westergren G. Equal Efficacy and Improved Tolerability with 50 mg Controlled-Release Metoprolol Compared with 100 mg Conventional Metoprolol in Hypertensive Patients. Am J Ther. 1994;1 (1):65–73.
  15. Руководство по нарушениям ритма сердца / под ред. Е. И. Чазова, С. П. Голицына. – М.: ГЭОТАР-Медиа, 2010. – 416 с.
  16. Waagstein F, Bristow MR, Swedberg K et al. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Metoprolol in Dilated Cardiomyopathy (MDC) Trial Study Group. Lancet. 1993;342 (8885):1441–1446.
  17. Gattis WA. Metoprolol CR / XL in the Treatment of Chronic Heart Failure. Pharmacotherapy. 2001;21 (5):604–613.
  18. Hjalmarson A, Goldstein S, Fagerberg B et al, for the MERIT–HF Study Group. Effects of controlled – release metoprolol on total mortality, hospitalizations, and well – being in patients with heart failure: the Metoprolol CR / XL Randomized Intervention Trial in congestive heart failure (MERIT–HF). JAMA. 2000;283 (10):1295–1302.
  19. Hedblad B, Wikstrand J, Janzon L et al. Low-dose metoprolol CR / XL and fluvastatin slow progression of carotid intima-media thickness: Main results from the Beta-Blocker Cholesterol-Lowering Asymptomatic Plaque Study (BCAPS). Circulation. 2001;103 (13):1721–1726.
  20. Wiklund O, Hulthe J, Wikstrand J et al. Effect of Controlled Release / Extended Release Metoprolol on Carotid Intima-Media Thickness in Patients With Hypercholesterolemia: A 3‑Year Randomized Study. Stroke. 2002;33 (2):572–557.
  21. Kendall M, Akhlaghi S, Hughes B, Lewis H. Is metoprolol CR / ZOK more selective than conventional metoprolol and atenolol? J Clin Pharmacol. 1990;30 (2 Suppl): S98–102.
  22. Löfdahl CG, Dahlöf C, Westergren G et al. Controlled-release metoprolol compared with atenolol in asthmatic patients: interaction with terbutaline. Eur J Clin Pharmacol. 1988;33 (Suppl): S25–32.
  23. Kerr D, MacDonald IA, Heller SR, Tattersall RB. Beta-adrenoceptor blockade and hypoglycaemia. A randomised, double-blind, placebo controlled comparison of metoprolol CR, atenolol and propranolol LA in normal subjects. Br J Clin Pharmacol. 1990;29 (6):685–693.
Evdokimova A. G., Kovalenko E. V., Lozhkina M. V. et al. Possibilities of administration of metoprolol succinate at cardiovascular diseases. Russian Heart Journal. 2012;11(5):272-276.

To access this material please log in or register

Register Authorize
Ru En